Bill reintroduced to speed biosimilars' eligibility for Medicare price negotiation

Single-source firm alert reports H.R. 10628 and S. 5571, the Biosimilars Access and Affordability Act, have been reintroduced to change when biosimilars qualify for Medicare negotiated pricing under the Inflation Reduction Act.